Aduhelm is supposed to be a treatment for alzheimers. It's about $28k per year.
The Medicare Trustees projected in August 2021 that the standard Part B premium for 2022 would be $158.50, which did not account for the costs of Aduhelm. In November, CMS raised the Part B premium to $170.10, in anticipation of the increased spending from Aduhelm.
However it hasn't been shown to actually help patients (themedicinemaker.com).
There appears to be little evidence on the likelihood of Aduhelm’s action translating into meaningful benefits for patients with Alzheimer’s.
Because it's super expensive and likely worthless, medicare decided to limit who can receive it (archive.ph).
Medicare will cover it only for people who receive it as participants in a clinical trial.
The FDA approved this snake oil despite 10 of 11 members of their advisory panel voting against approval.
Aduhelm is supposed to be a treatment for alzheimers. It's about $28k per year.
> The Medicare Trustees projected in August 2021 that the standard Part B premium for 2022 would be $158.50, which did not account for the costs of Aduhelm. In November, CMS raised the Part B premium to $170.10, in anticipation of the increased spending from Aduhelm.
However it hasn't been shown to [actually help patients](https://themedicinemaker.com/business-regulation/addressing-the-aduhelm-controversy).
> There appears to be little evidence on the likelihood of Aduhelm’s action translating into meaningful benefits for patients with Alzheimer’s.
Because it's super expensive and likely worthless, medicare decided to [limit who can receive it](https://archive.ph/UJpCS).
> Medicare will cover it only for people who receive it as participants in a clinical trial.
The FDA approved this snake oil despite 10 of 11 members of their advisory panel voting against approval.
(post is archived)